Comparative Pharmacology
Head-to-head clinical analysis: SEMPREX D versus TRIPROLIDINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SEMPREX D versus TRIPROLIDINE HYDROCHLORIDE.
SEMPREX-D vs TRIPROLIDINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
SEMPREX-D combines acrivastine, a histamine H1 receptor antagonist, and pseudoephedrine, a sympathomimetic amine vasoconstrictor. Acrivastine blocks peripheral histamine-mediated effects, while pseudoephedrine constricts nasal blood vessels to reduce congestion.
Competitive antagonist of histamine H1 receptors; inhibits histamine-mediated vasodilation, increased capillary permeability, and bronchoconstriction in allergic reactions.
1 capsule orally every 12 hours; each capsule contains acrivastine 8 mg and pseudoephedrine 60 mg.
2.5 mg orally every 4-6 hours as needed; maximum 10 mg per 24 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 8-12 hours, allowing twice-daily dosing.
Terminal elimination half-life approximately 3–4 hours in healthy adults; prolonged in renal impairment (up to 12 hours).
Renal (approx. 60% as unchanged drug and metabolites), biliary/fecal (approx. 40%).
Renal (primarily as metabolites; ~70% recovered in urine within 24 hours, <5% unchanged). Fecal elimination is minor.
Category C
Category A/B
Antihistamine/Decongestant Combination
Antihistamine